Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186740 · ClinicalTrials.gov registry record · NA
ProVee Urethral Expander System IDE Study (ProVIDE)
A NA study of Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical.
- Active
- Registry status
- NA
- Development phase
- 221
- Enrollment target
- 17
- Study locations
NCT05186740: Active NA study of Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms, sponsored by ProVerum Medical.
NCT05186740 is a NA study of Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms that is active but no longer recruiting, run by ProVerum Medical. The registered enrollment target is 221 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05186740, a NA study of Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms, is active but no longer recruiting, sponsored by ProVerum Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 221 participants
- Enrollment target
- 17
- Study locations
Study Summary
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH).
Primary Outcome
This includes the rate of device or procedure related serious adverse events through 12-months.
Conditions Studied
Interventions
- DEVICE ProVee Urethral Expander System
- PROCEDURE Urethral Access Sheath
Study Locations (17)
Florida
- Urological Research Network Corp - Hialeah
- Advanced Urology Institute - Palm Coast
- Tampa Urology LLC - Tampa
- Avant Concierge Urology - Winter Garden
Texas
- Midtown Urology Assoc. - Austin
- Urology Austin - Austin
- Houston Methodist - Houston
Illinois
- Comprehensive Urologic Care - Lake Barrington
- Southern Illinois University School of Medicine - Springfield
New York
- Mount Sinai - New York
- Manhattan Medical Research Practice - New York
California
- Golden State Urology - Sacramento
Nevada
- Sheldon Freedman MD - Las Vegas
North Carolina
- Associated Urologists of North Carolina - Raleigh
Virginia
- Urology of Virginia - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2028-12 |
| Phase | NA |
What the registry record for NCT05186740 still lists
NCT05186740 is an interventional study that assigns participants to a tested intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 2 interventions - of which ProVee Urethral Expander System is the first listed.
NCT05186740 lists 17 locations in 10 states (Florida, Texas, Illinois).
Frequently Asked Questions
What is clinical trial NCT05186740 about?
NCT05186740 is a clinical study titled "ProVee Urethral Expander System IDE Study (ProVIDE)". A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH).
What is the current status of trial NCT05186740?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 221 participants. The study started on 2022-06-09. Estimated completion is 2028-12.
What conditions does trial NCT05186740 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms.
What interventions are being tested in trial NCT05186740?
The interventions under investigation include: ProVee Urethral Expander System (DEVICE), Urethral Access Sheath (PROCEDURE).
Who is sponsoring clinical trial NCT05186740?
This trial is sponsored by ProVerum Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186740 being conducted?
This trial has 17 study locations across California, Florida, Illinois, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05186740's enrollment target sits among peer trials
221 481st of 2000 higher than 1,520 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI